Atopic dermatitis: Tofacitinib, an option for refractory disease | Zendy

Berbert Ferreira Sineida | Zendy; Berbert Ferreira Rachel | Zendy; Scheinberg Morton Aaron | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Atopic dermatitis: Tofacitinib, an option for refractory disease

Author(s) -

Berbert Ferreira Sineida,

Berbert Ferreira Rachel,

Scheinberg Morton Aaron

Publication year - 2020

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.3325

Subject(s) - tofacitinib , medicine , atopic dermatitis , refractory (planetary science) , dermatology , disease , quality of life (healthcare) , rheumatoid arthritis , physics , nursing , astrobiology

Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate‐severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research